VANCOUVER, British Columbia, June 10, 2004 (PRIMEZONE) -- ProtoKinetix, Inc. (OTCBB:PKTX) is pleased to announce that it has received its first antibody from BioCurex. This is a monoclonal antibody which will form the basis upon which future ProtoKinetix researchers will develop a therapy for treating cancer. The research upon this antibody will be coordinated through our ongoing collaboration with Perigene, with the work carried out by an international team of scientists in both Canada and in France.
This antibody will be the first to be tested for suitability of development into a therapy against cancer. We are very pleased with the testing that has been conducted to date and are going forward with confidence as we use well proven science to progress from where we are now to an effective therapeutic agent.
Safe Harbor
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors, Dr. John Todd, President